Austin, TX 9/28/2007 9:51:02 PM
Speak with other shareholders about: (PINKSHEETS: HSXI), (OTC BB: BSLM), (OTC Bulletin Board: OLGX), (OTCBB: DVNNF), (PINK SHEETS: OSSG), (NASDAQ: HLEX)
AUSTIN, TX: September 28, 2007 – Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the “Chat Live” button at the top.
----------------------------------------------------------
Chat real-time with other investors about this HSXI news release,
by clicking this link: http://www.stockwire.com/HSXI
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=HSXI
HealthSonix, Inc. (PINKSHEETS: HSXI)
HealthSonix, Inc. closed at $0.24 Thursday, trading 181,750 shares.
Company News- September 26, 2007 HealthSonix and Abbott Laboratories Launch Innovative Combination Therapy Program for Patients With Advanced Rheumatoid Arthritis
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) announced Wednesday that the joint marketing program with Abbott Laboratories has commenced in Southern Ontario, Canada. The program is the first of its kind and offers Rheumatologists the option of prescribing "combination therapy" for patients with advanced rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
"The guidelines published by the American College of Rheumatology [ACR] for rheumatoid arthritis state that 'the ultimate goals in managing RA are to prevent or control joint damage, prevent loss of function, and decrease pain,'" said Dieter D. Doederlein, Vice President Corporate Development of HealthSonix. "To maintain joint function, the guidelines suggest that 'regular participation in dynamic and even aerobic conditioning exercise programs improves joint mobility, muscle strength, aerobic fitness and function, and psychological well being without increasing fatigue or joint symptoms.' That is why the combination therapy now offered by Abbott Laboratories and HealthSonix is a significant new development for both rheumatologists and their patients," said Doederlein.
Abbott's biologic therapy works against the inflammatory process like other TNF blockers and has been shown to be effective in controlling symptoms of the disease. The product is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.
The benefits of AquaSonix Therapy for the patient with immunological disorders include provision of a reduced weight-bearing environment in which to exercise; improvement in Range Of Motion; reduction in joint and muscle stiffness; improvement in the willingness to move; improvement in functional strength and functional mobility; improvement in social and psychological factors.
"This new program represents a significant development in the fight against arthritis because the ACR guidelines stress that the combination of medications and non-pharmacological therapies is the optimal way to treat the patients," said Doederlein.
About HealthSonix, Inc. (PINKSHEETS: HSXI)
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects. More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
----------------------------------------------------------
Chat real-time with other investors about this BSLM news release,
by clicking this link: http://www.stockwire.com/BSLM
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=BSLM
Bio Solutions Manufacturing, Inc. (OTC BB: BSLM)
Bio Solutions Manufacturing, Inc. closed at $0.125 Thursday, trading 196,526 shares.
Company News- September 28, 2007: Bio Solutions Manufacturing Signs Lease Agreement for R&D Facility
Bio Solutions Manufacturing, Inc. (OTC BB: BSLM) (Frankfurt: B2T) announced earlier today that it has signed a commercial lease agreement for a Research and Development Center in Hawley, Pennsylvania. The initial task is to produce samples of ASTM-nationally approved bio-diesel from liquid brown trap grease over the next several weeks, and to then provide a suitable environment to demonstrate this process to haulers, blenders, and commercial and municipal waste disposal officials interested in turning this "messy nuisance" into a valuable resource.
Peter Chapin, President of the Company's Bio-Extraction Services subsidiary, stated, "This facility is the next step in turning our technical expertise and proprietary technology into a viable business opportunity. We are looking to combine our patent pending bio-extraction devices, which are installed in over thirty different locations to separate grease from water, our proprietary formulations for handling grease, and our experience in handling liquid brown trap grease in a variety of commercial and municipal locations, to establish ourselves as leaders in the bio-diesel market.
"We believe that bolting our proven front end' proprietary pre-screening technology with back end' off-the-shelf conversion methods should reduce the technology risks associated with the bio-diesel process. In addition, we have developed a cookie-cutter' design philosophy for our proposed plants that are scalar, modular, and designed to provide convenient geographic coverage, which is unlike our competitors' approach of large, stand-alone plants."
About Bio Solutions Manufacturing, Inc.
Bio Solutions Manufacturing has developed microbiological products for waste bioremediation. The Company's products are currently used by many municipal collection systems and food service facilities in the United States. The Company's products have been approved by municipalities for use in food service facilities that produce waste products introduced into the municipal collection systems. The Company's products treat waste in an environmentally friendly and safe manner in compliance with Federal and State government standards.
The Company has developed a line of environmentally friendly cleaning products that include all-purpose cleaner, carpet cleaner, concrete and asphalt cleaner, and floor soap. In addition, the Company is developing a unique, patent-pending grease extractor to be used in conjunction with bioremediation solutions to extract desired oil and grease to be converted into value-added product, such as biodiesel fuel.
----------------------------------------------------------
Chat real-time with other investors about this OLGX news release,
by clicking this link: http://www.stockwire.com/OLGX
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=OLGX
Osteologix Inc. (OTC Bulletin Board: OLGX)
Osteologix Inc. closed at $1.17 Thursday, trading 2,000 shares.
Company News- September 28, 2007 Osteologix to Present at NASDAQ MarketSite During EQUITIES 2007 Transatlantic Conference
Osteologix Inc. (OTC Bulletin Board: OLGX), a specialty pharmaceutical company developing innovative therapies for the treatment and prevention of musculoskeletal diseases, announced earlier today that Philip J. Young, President and CEO of Osteologix, will present a corporate overview highlighting the Company's Phase II Osteoporosis clinical trial, the STRONG Study, Friday, September 28 at 8:50 a.m. during the EQUITIES 2007 Transatlantic Conference to be held at to be held at the NASDAQ MarketSite in New York City. A live audio webcast and slide presentation will be available via the internet by visiting www.equitiesmagazine.com.
About Osteologix
Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company's vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
About NB S101
NB S101 is a novel dual acting bone agent, or DABA, the active component of which significantly improves bone mineral density and reduces fracture risk. In preclinical studies, NB S101 has demonstrated significant beneficial effects by reducing bone resorption and increasing high quality strong bone formation and bone mineralization. This dual action on bone- a significant medical need- suggests that NB S101 could fundamentally change the treatment paradigm of patients with osteoporosis. Importantly, NB S101 helps to build bone in a manner similar to the body's own metabolic processes by rebalancing bone metabolism in a way that favors strong bone development. Osteologix has a competitive intellectual property position. A key patent for NB S101 has been issued in EU providing protection out to 2024, with US patents published and currently pending.
The NB S101 Program and the STRONG Study
Osteologix has conducted extensive preclinical and clinical drug research with its proprietary DABA, NB S101. The Phase II STRONG Study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group dose response study in 289 postmenopausal women. The results will provide data on the effects of NB S101 on bone metabolism, bone mineral density, safety, tolerability and pharmacokinetics. The primary endpoint in the trial is the change in patients' bone resorption, as measured by the biochemical marker CTX-1. Data from this trial will be reported in the fourth quarter of 2007.
About Osteoporosis
Osteoporosis is the most common bone disease in humans and, according to the National Osteoporosis Foundation (NOF), 10 million Americans are estimated to have the disease and almost 34 million more are estimated to have osteopenia or low bone mass, placing them at increased risk for osteoporosis. The most severe consequence of osteoporosis is skeletal fracture. Osteoporosis is responsible for more than 1.5 million fractures annually and direct expenditures for hip fractures are estimated to cost society more than $18 billion annually. According to NOF, one in two women and one in four men over age 50 can be expected to have an osteoporosis-related fracture at some time.
----------------------------------------------------------
Chat real-time with other investors about this DVNNF news release,
by clicking this link: http://www.stockwire.com/DVNNF
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=DVNNF
Devine Entertainment Corporation (OTCBB: DVNNF)
Devine Entertainment Corporation closed at $0.14 Thursday, trading 17,000 shares.
Company News- September 28, 2007: Devine Entertainment Releases Transcript of Recent Investor Conference Call Focusing on Revenue Guidance and Growth Strategies
Devine Entertainment Corporation (OTCBB: DVNNF), capitalizing on the global distribution of award-winning original film and television content, announced earlier today they invite interested investors to read the complete transcript of the Company's September 26 investor conference call.
During the call, Company President and Chief Executive Officer David Devine updated investors on Devine's latest revenue and earnings guidance, which project revenue increases for the first three quarters of calendar 2007 of $5.5 million (Canadian), a 16-fold increase over the same period the previous year.
"I'm very happy to say that our focus and our aggressive business plan has delivered exceptional revenues and compelling shareholder value," Mr. Devine told investors.
He also detailed the Company's key initiatives to continue growth through international distribution agreements, and anticipated new productions and acquisitions to expand Devine's library of film and television content.
"In building the family and children's library over the course of a number of years, we had a $31 million investment in that library and that $31 million investment has recouped and all of our 19 children and family films are now in profit," Mr. Devine said during the call. "That's something rare in the film business to go 19 out of 19 recouping, successful and continuing to sell." To continue the Company's progress, Devine has recently entered the primetime television drama market, with a new series premiering in November, entitled "Across the River to Motor City." Mr. Devine remarked, "This is a testament to our desire to vertically integrate the company to continue to create, continue to produce and continue to distribute, but evolve past children's and family into primetime and further evolve into the feature film market." To read or download a complete transcript of the September 26 conference call.
About Devine Entertainment
Devine Entertainment Corporation develops, creates, and produces award-winning television programming and feature films for worldwide distribution across multiple TV broadcast networks, cable and satellite networks, DVD and Internet markets. Specializing in cultural and educational programming as well as primetime drama and comedy entertainment programming, the Company's titles have garnered more than 120 international film and television industry awards, including five Emmy and five Gemini Awards. The Company partners with leading international distributors, broadcasters and co-producers, such as Sony BMG, Rogers Media and The Carrere Group of France, to produce and distribute its award-winning film and television titles. Among Devine's critically-acclaimed productions are its cultural and educational film series on history's landmark Composers', Inventors' and Artists', which have been broadcast in more than 50 countries. The Company continues to expand its proprietary library of high-quality film and television content. Among its general-audience primetime programming is the acclaimed one-hour mystery series, "Across the River to Motor City," delivered to broadcasters worldwide in 2007. Headquartered in Toronto, the Company's common shares trade on the NASD OTCBB market in the U.S. under the symbol DVNNF. The Company's corporate website is www.devine-ent.com.
----------------------------------------------------------
Chat real-time with other investors about this OSSG news release,
by clicking this link: http://www.stockwire.com/OSSG
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=OSSG
Online Sales Strategies, Inc. (PINK SHEETS: OSSG)
Online Sales Strategies, Inc. closed at $0.012 Thursday, trading 159,900 shares.
Company News- September 28, 2007 Online Sales Strategies, Inc. (OSSG) Finalizes Sale of GIGcom, Inc. to Rocket City Enterprises, Inc. (RCTY)
Online Sales Strategies, Inc. (PINK SHEETS: OSSG) ("OSSG" or "the Company") announced earlier today that it has finalized the sale of subsidiary GIGcom, Inc., a leading full-service online solutions provider for small and medium businesses, to Rocket City Enterprises, Inc. for shares of restricted stock and a one-time cash payment. Matthew A. Brown, President of Online Sales Strategies, Inc. will continue in his capacity as President of GIGcom and will be joining the Rocket City team as President and Chief of Technology.
Mr. Brown explains, "Rocket City has built a strong, well-deserved reputation for efficient business management while continuing to live up to its tradition of technological innovation in the software and automobile industry. By bringing our own products to the table, we're confident that GIGcom will strengthen and diversify Rocket City's business model and allow Online Sales Strategies to strengthen its reach within the marketplace as well." Jeff Roman, CEO and Chairman of Rocket City stated, "We see this acquisition as the next logical step in our long-term strategy. By acquiring GIGcom, Rocket City will be able to utilize its suite of products and services and tap into the next generation of the internet. This creates a very large potential customer base for Rocket City's future. At the same time, we believe that GIGcom's services will fit seamlessly with Rocket City's business, extending our end-to-end solutions. We think it would be hard to find a more complementary match for these two businesses than what this combination provides."
About Online Sales Strategies Inc.
Online Sales Strategies' mission is to become a leading provider of all necessary resources to successfully manage and operate online sales and software related businesses. AuctionSound is an ASP application for online asset management and was created for eBay Trading Assistants to manage online sales and consignment products which includes customer management, listing tools, auction templates, image hosting, shipping and financial reporting all from one interface. The AuctionSound platforms provide a turnkey solution to the product-to-cash cycle across multiple marketplaces and our suite of eCommerce products allow customers the flexibility to manage their customers' shopping experience. Our customers range from independent retailers striving for an online presence to entire franchise chains seeking an intelligent solution to manage their network of stores. OSSG continues to develop strong relationships with both customers and peripheral service providers to bridge the digital divide between consumers and businesses. AuctionSound is a certified eBay compatible application that supports various business models in several countries. For more information, please visit our website at: http://www.onlinesalesstrategies.com.
About Rocket City Enterprises, Inc.:
Rocket City Enterprises, Inc. is a publicly traded company (Pink Sheets: RCTY) and was formed to acquire, manage, supervise and operate corporations specializing in auction services, e-commerce, software development, technology and retail automotive operations. RocketCity is an online solution provider for a variety of web-based platforms and offers proprietary software, technology, personnel and design solutions to hundreds of automotive dealerships around the country and additional partners throughout the marketplace. Visit them on the web at www.RCAU.com to learn more.
----------------------------------------------------------
Chat real-time with other investors about this HLEX news release,
by clicking this link: http://www.stockwire.com/HLEX
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=HLEX
HealthExtras, Inc. (NASDAQ: HLEX)
HealthExtras, Inc. closed at $28.23 Thursday, trading 273,900 shares.
Company News- September 28, 2007 Medical Card System, Inc. Selects Catalyst Rx to Provide Pharmacy Benefit Management Services
HealthExtras, Inc. (NASDAQ: HLEX) announced earlier today that its Pharmacy Benefit Management (PBM) division, Catalyst Rx was selected by Medical Card System, Inc. (MCS) to provide PBM services to the Puerto Rico based health plan. Catalyst Rx will serve as the PBM commencing December 1, 2007, for MCS's Commercial business and commencing January 1, 2008, for MCS's Medicare Part D (Classicare) business. The selection of Catalyst Rx and applicable terms are subject to final contract execution.
"MCS's selection of Catalyst Rx reflects continued success in our efforts to provide clients with both heightened performance accountability and innovative solutions to managing prescription benefits," said David T. Blair, Chief Executive Officer of HealthExtras. "We look forward to working with MCS on a collaborative basis to deliver local market-focused management of prescription benefits and to provide MCS's members with the highest level of service." "Catalyst Rx's commitment to an extensive Center of Excellence with employees located in Puerto Rico, track record of success with numerous efficient PBM conversions and reputation for exceptional service should improve both the quality and value of pharmacy benefits for our members in Puerto Rico," said Gregory H. Wolf, Chief Executive Officer of MCS.
Catalyst Rx has had success in serving managed care companies by aligning its clinically-focused Centers of Excellence with the operations of the health plan. This strategy has proven to be effective in improving member communications, formulary compliance and overall member satisfaction. Catalyst has already begun the initial phases of its implementation process in Puerto Rico, focused on local market hiring initiatives, data processing, information technology platforms and member communications.
HealthExtras management team will provide more details on this contract and other corporate developments in conjunction with its next regularly scheduled conference call now scheduled for November 7, 2007. During that call the Company will discuss the financial impact of the MCS contract including the timing and extent of anticipated upfront implementation expenses as well as post-implementation revenue and earnings contributions.
About HealthExtras (www.healthextras.com)
HealthExtras, Inc. is a full-service pharmacy management company. Its clients include self-insured employers, including state and local governments, third-party administrators, managed care organizations and individuals. The Company's integrated pharmacy benefit management services marketed under the name Catalyst Rx include: claims processing, benefit design consultation, drug utilization review, formulary management, drug data analysis services, and mail service and specialty services. Additionally, the Company operates a national retail pharmacy network with over 59,000 participating pharmacies.
About Medical Card System, Inc. (www.medicalcardsystem.com)
Medical Card System Inc. (MCS) is the second largest health insurance company in Puerto Rico with over 725,000 Commercial, Medicare, and Medicaid (Reforma) members. MCS offers custom-made products and guarantees competitive rates that satisfy the health care needs of all segments of the population in Puerto Rico. MCS is a leader in health care administration and offers personalized customer service, quality and efficiency in clinical care, and flexibility in the design of plans and models of access. The company has a wide network of participating providers consisting of over 12,000 physicians, pharmacies, dentists, labs and hospitals.
----------------------------------------------------------
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. Likewise, Stockwire.com is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
